CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 187 filers reported holding CRISPR THERAPEUTICS AG in Q3 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,148,000 | -30.9% | 17,567 | +71.0% | 0.01% | -44.4% |
Q2 2021 | $1,662,000 | +355.3% | 10,271 | +19.4% | 0.02% | -21.7% |
Q1 2020 | $365,000 | -66.3% | 8,600 | -67.4% | 0.02% | -28.1% |
Q3 2019 | $1,083,000 | +78.4% | 26,420 | +92.8% | 0.03% | +18.5% |
Q3 2018 | $607,000 | – | 13,700 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |